Our Services
Medical Information
Helpful Resources
Published on: 3/7/2026
Brilinta (ticagrelor) is a blood thinner that prevents platelets from clumping, so reduced clotting, mild bruising, or slightly longer bleeding times are usually signs the medication is working as intended to lower your risk of heart attack and stroke. However, certain symptoms—such as heavy or uncontrolled bleeding, blood in urine or stool, severe headaches, or unusual bruising—are red flags that require urgent medical care.
Several factors can influence bleeding while on Brilinta, including concurrent use of aspirin or NSAIDs, underlying bleeding disorders like von Willebrand disease (vWD), and lifestyle habits. Never stop Brilinta on your own, as doing so can dramatically increase your risk of a clot-related emergency.
If you're unsure whether your bleeding is normal or concerning, take a free, instant, online symptom check to evaluate your symptoms in minutes. It's a smart, private first step to help you understand what's happening and decide whether to call your doctor, seek urgent care, or simply monitor at home—giving you clarity and confidence in your next move.
Reviewed for medical accuracy: 06/24/2026
Not seeing your question? No worries.
Submit your own QuestionIf you're taking Brilinta and notice that you bruise more easily, bleed longer, or your blood doesn't clot like it used to, it can feel scary. That reaction is completely understandable.
Here's the truth: Brilinta is designed to reduce your blood's ability to clot. In most cases, that's not a side effect — it's the goal of the medication.
Let's break down why this happens, when it's expected, when it's not, and what medically approved steps you should take next.
Brilinta (ticagrelor) is a prescription antiplatelet medication. It's commonly prescribed after:
Brilinta works by preventing platelets (tiny blood cells) from sticking together. Platelets are what form clots to stop bleeding.
That's important because:
So if your blood isn't clotting as quickly as before, that means the medication is working.
However, there's a balance. Too much bleeding is not normal and should never be ignored.
If you're on Brilinta, slower clotting is expected. But several factors can influence how noticeable it feels.
Brilinta blocks a receptor on platelets called P2Y12. When this receptor is blocked:
Common, mild effects include:
These are known and expected side effects.
Many patients are prescribed Brilinta plus low-dose aspirin.
This combination (called dual antiplatelet therapy) is standard after a heart attack or stent placement. But it increases bleeding risk compared to taking either drug alone.
If you're experiencing more bleeding than expected, your doctor may need to reassess:
Never stop either medication without medical guidance.
Some people have a bleeding disorder and don't realize it until they take a medication like Brilinta.
One example is von Willebrand Disease (vWD) — a common inherited bleeding disorder that affects how blood clots.
Signs of vWD may include:
If you've had unexplained bleeding issues throughout your life—even before starting Brilinta—it's worth exploring whether an underlying condition like von Willebrand Disease (vWD) could be contributing to your symptoms, so you can have a more informed discussion with your doctor.
This does not replace medical care — but it can help guide your next conversation.
It's important to know the difference between normal medication effects and dangerous bleeding.
These are typically manageable and should be reported at routine follow-ups.
Seek immediate medical care if you experience:
These could signal internal bleeding or bleeding in the brain — rare but serious complications.
If you're unsure, it's safer to seek medical evaluation.
This is critical.
Stopping Brilinta suddenly — especially after a recent stent or heart attack — can significantly increase your risk of:
For many patients, the risk of stopping the medication is far greater than the risk of manageable bleeding.
If bleeding is concerning, your cardiologist may:
But that decision must be made by a physician.
If you're worried about clotting or bleeding while on Brilinta, here's what to do.
Write down:
Specific details help your doctor assess severity.
Some drugs increase bleeding risk when combined with Brilinta:
Do not stop medications without guidance — but inform your doctor about everything you take.
Your doctor may order:
Brilinta itself does not usually change platelet counts — it changes how platelets function.
Have a direct conversation with your doctor about:
The goal is balanced care — protecting your heart while minimizing bleeding risk.
While on Brilinta:
These small steps make a meaningful difference.
It's normal to feel uneasy when your blood doesn't clot like it used to.
But remember:
At the same time, bleeding risks are real and should be monitored carefully.
The key is balance — not panic.
You should speak to a doctor urgently or seek emergency care if you experience:
Even if you're unsure, it's better to err on the side of caution.
For non-emergency concerns, schedule an appointment with your cardiologist or primary care physician to review your symptoms.
If you're scared of Brilinta because your blood isn't clotting the way it used to, that fear is understandable. But in most cases, what you're noticing is the medication working as intended.
Still, bleeding should always be evaluated thoughtfully — especially if it's new, worsening, or severe.
Consider:
Most importantly, never stop Brilinta without medical supervision.
If something feels serious or life-threatening, speak to a doctor immediately. Your safety — both from clots and from bleeding — depends on careful, informed medical guidance.
(References)
* Schulz H, Schömig A, Neumann FJ, et al. Management of Bleeding Complications in Patients on Dual Antiplatelet Therapy with Aspirin and P2Y12 Inhibitors. J Clin Med. 2021;10(14):3152.
* Parikh C, Angiolillo DJ. Ticagrelor: A P2Y12 Inhibitor With Unique Clinical Features. Am J Cardiovasc Drugs. 2020;20(5):427-440.
* Zhang B, Cao Y, Xu T, et al. Ticagrelor Resistance: Current Knowledge and Management. Front Pharmacol. 2022;13:843187.
* Pavan S, Barco S, Di Marco F, et al. Reversal of ticagrelor-induced platelet inhibition in patients with acute bleeding or requiring urgent surgery. A systematic review. J Thromb Haemost. 2018;16(8):1501-1510.
* Capodanno D, Angiolillo DJ. Ticagrelor: a comprehensive review on pharmacology, clinical evidence and future directions. Eur Heart J Cardiovasc Pharmacother. 2016;2(1):3-15.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.